Screening for YAP Inhibitors Identifies Statins as Modulators of Fibrosis
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis is a lung disease with limited therapeutic options that is characterized by pathological fibroblast activation and aberrant lung remodeling with scar formation. YAP (Yes-associated protein) is a transcriptional coactivator that mediates mechanical and biochemical signals controlling fibroblast activation. In this study, we developed a high-throughput small-molecule screen for YAP inhibitors in primary human lung fibroblasts. Multiple HMG-CoA (hydroxymethylglutaryl-coenzyme A) reductase inhibitors (statins) were found to inhibit YAP nuclear localization via induction of YAP phosphorylation, cytoplasmic retention, and degradation. We further show that the mevalonate pathway regulates YAP activation, and that simvastatin treatment reduces fibrosis markers in activated human lung fibroblasts and in the bleomycin mouse model of pulmonary fibrosis. Finally, we show that simvastatin modulates YAP in vivo in mouse lung fibroblasts. Our results highlight the potential of small-molecule screens for YAP inhibitors and provide a mechanism for the antifibrotic activity of statins in idiopathic pulmonary fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Statins, including simvastatin, have also shown antifibrotic potential in preclinical studies by promoting YAP cytoplasmic retention and inactivation, offering opportunities for drug repurposing (144, 145).”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“Plates were monitored for cell density, percentage of nuclear YAP(1) cells in control wells, and z-scores (26), and rescreened if deemed necessary.”
BackgroundRole of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Zhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092 · cited 6×
“Accordingly, statins induced a marked increase in the phosphorylation of serine 397 (pS397) (Figures 3A and 3B), which marks YAP for proteasomal degradation (28).”
BackgroundInfluentialTEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
The Biology of YAP/TAZ: Hippo Signaling and Beyond
Piccolo, S., Dupont, S., & Cordenonsi, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00005.2014 · Cited by 1,802 · cited 2×
“Statin treatment was associated with decreased cell numbers (Figure E3A), probably due to inhibition of proproliferative YAP/TAZ signaling (27).”
BackgroundMethodSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Mechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667 · cited 2×
“YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif) are transcriptional coactivators that when active translocate to the nucleus and induce the expression of a wide range of genes, controlling cell proliferation, survival, and migration (10).”
BackgroundAragona, M., Panciera, T., Manfrin, A., Giulitti, S., Michielin, F., Elvassore, N., Dupont, S., & Piccolo, S. (2013) · Cell · doi:10.1016/j.cell.2013.07.042 · Cited by 1,651 · cited 8×
“In our investigation of the antifibrotic potential of statins, we also found that statins Santos, Pantano, Pronzati, et al.: IPF Drug Screen: Statins Inhibit YAP in Lung Fibroblasts 489 prevented HLF activation by TGF-b, reducing the expression of profibrotic genes (CTGF, CYR61, ACTA2, and COL1A1) and preventing actin…”
BackgroundInfluentialStructural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644 · cited 1×
“The Mevalonate Pathway Controls YAP Localization and Activity Statins are best known for their cholesterollowering effects through targeting of HMGCR (HMG-CoA reductase) (30).”
BackgroundLiu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S.-J., Anders, R. A., Liu, J. O., & Pan, D. (2012) · Genes & Development · doi:10.1101/gad.192856.112 · Cited by 1,452
A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF β-TRCP
Zhao, B., Li, L., Tumaneng, K., Wang, C.-Y., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1843810 · Cited by 1,418
TGF-β and the TGF-β family: context-dependent roles in cell and tissue physiology
Morikawa, M., Derynck, R., & Miyazono, K. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021873 · Cited by 1,321
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · cited 1×
“Idiopathic pulmonary fibrosis (IPF) is an incurable disease that leads to progressive respiratory decline with high morbidity and mortality (1).”
BackgroundRecent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
YAP/TAZ upstream signals and downstream responses
Totaro, A., Panciera, T., & Piccolo, S. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0142-z · Cited by 1,086
Fibroblasts in fibrosis: novel roles and mediators
Kendall, R. T., & Feghali-Bostwick, C. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00123 · Cited by 1,082 · cited 1×
“Fibroblasts are the principal effector cells in IPF, being responsible for the synthesis of excess extracellular matrix components (5).”
BackgroundMoeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007 · cited 1×
“Indeed, the vast majority of studies in the bleomycin model use a preventive regimen, which does not distinguish between drugs that interfere with the inflammatory response to lung injury and fibrosis (62).”
BackgroundAnti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
Jain, M. K., & Ridker, P. M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1901 · Cited by 915 · cited 2×
“Thus, the reported benefits of statins given at the time of initial injury in prior studies could be due to their antiinflammatory properties, rather than antifibrotic inactivation of fibroblasts (41).”
BackgroundMechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis
Liu, F., Lagares, D., Choi, K. M., Stopfer, L., Marinković, A., Vrbanac, V., Probst, C. K., Hiemer, S. E., Sisson, T. H., Horowitz, J. C., et al. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00300.2014 · Cited by 874
Self-citationMetabolic control of YAP and TAZ by the mevalonate pathway
Sorrentino, G., Ruggeri, N., Specchia, V., Cordenonsi, M., Mano, M., Dupont, S., Manfrin, A., Ingallina, E., Sommaggio, R., Piazza, S., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2936 · Cited by 776 · cited 3×
“Cerivastatin and simvastatin have been shown to induce S127-YAP phosphorylation in MDA-MB-231 breast cancer cells (19, 20), but not in human pancreatic cancer cells (55).”
BackgroundSirtori, C. R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.03.002 · Cited by 691 · cited 1×
“Statins target the sterol biosynthetic pathway and are widely used to lower blood cholesterol levels and prevent heart disease and strokes (18).”
BackgroundAcellular Normal and Fibrotic Human Lung Matrices as a Culture System for In Vitro Investigation
Booth, A. J., Hadley, R., Cornett, A. M., Dreffs, A. A., Matthes, S. A., Tsui, J. L., Weiss, K., Horowitz, J. C., Fiore, V. F., Barker, T. H., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0754oc · Cited by 665 · cited 1×
“Myofibroblast differentiation is directed by both biochemical and biomechanical signals, such as TGF-b (transforming growth factor-b) (7) and stiffening of the extracellular matrix in fibrosis (8).”
BackgroundMolecular Targets in Pulmonary Fibrosis
Scotton, C. J., & Chambers, R. C. (2007) · Chest · doi:10.1378/chest.06-2568 · Cited by 538
Zhang, K., Rekhter, M. D., Gordon, D., & Phan, S. H. (1994) · PubMed · Cited by 480
The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases.
Friesen, J. A., & Rodwell, V. W. (2004) · Genome biology · doi:10.1186/gb-2004-5-11-248 · Cited by 474
YAP/TAZ Are Mechanoregulators of TGF-β-Smad Signaling and Renal Fibrogenesis
Szeto, S. G., Narimatsu, M., Lu, M., He, X., Sidiqi, A. M., Tolosa, M. F., Chan, L., De Freitas, K., Bialik, J. F., Majumder, S., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015050499 · Cited by 462 · cited 1×
“In murine kidney and liver models, inhibition of YAP/TAZ was shown to prevent fibroblast or hepatic stellate cell activation and to reduce fibrogenesis (15, 16).”
BackgroundSignaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge
Piersma, B., Bank, R. A., & Boersema, M. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00059 · Cited by 442
Jenkins, R. G., Moore, B. B., Chambers, R. C., Eickelberg, O., Königshoff, M., Kolb, M., Laurent, G. J., Nanthakumar, C. B., Olman, M. A., Pardo, A., et al. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0096st · Cited by 435
Self-citationThe Hippo pathway effector YAP controls mouse hepatic stellate cell activation
Mannaerts, I., Leite, S. B., Verhulst, S., Claerhout, S., Eysackers, N., Thoen, L. F. R., Hoorens, A., Reynaert, H., Halder, G., & van Grunsven, L. A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.011 · Cited by 410 · cited 1×
“In murine kidney and liver models, inhibition of YAP/TAZ was shown to prevent fibroblast or hepatic stellate cell activation and to reduce fibrogenesis (15, 16).”
BackgroundRole of Lung Pericytes and Resident Fibroblasts in the Pathogenesis of Pulmonary Fibrosis
Hung, C., Linn, G., Chow, Y.-H., Kobayashi, A., Mittelsteadt, K., Altemeier, W. A., Gharib, S. A., Schnapp, L. M., & Duffield, J. S. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201212-2297oc · Cited by 385 · cited 1×
“Because of the lack of broad fibroblast markers (45), we focused on lung cells expressing high levels of collagen, as this population is highly enriched in fibroblasts (46).”
BackgroundRho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification
Roberts, P. J., Mitin, N., Keller, P. J., Chenette, E. J., Madigan, J. P., Currin, R. O., Cox, A. D., Wilson, O., Kirschmeier, P., & Der, C. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800882200 · Cited by 362 · cited 12×
“We thus investigated whether YAP inactivation by statins could be reversed by addition of GGPP to the culture media.”
BackgroundInfluentialWang, Z., Wu, Y., Wang, H., Zhang, Y., Mei, L., Fang, X., Zhang, X., Zhang, F., Chen, H., Liu, Y., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319190110 · Cited by 316 · cited 3×
“Cerivastatin and simvastatin have been shown to induce S127-YAP phosphorylation in MDA-MB-231 breast cancer cells (19, 20), but not in human pancreatic cancer cells (55).”
BackgroundGeorge, T. C., Fanning, S. L., Fitzgeral-Bocarsly, P., Medeiros, R. B., Highfill, S., Shimizu, Y., Hall, B. E., Frost, K., Basiji, D., Ortyn, W. E., et al. (2006) · Journal of Immunological Methods · doi:10.1016/j.jim.2006.01.018 · Cited by 249 · cited 2×
“Multiple events of “nuclear” or “cytoplasmic” YAP staining could be detected in HLFs costained for YAP and nuclei (with DAPI) (Figure 7A).”
MethodSelective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis
Haak, A. J., Kostallari, E., Sicard, D., Ligresti, G., Choi, K. M., Caporarello, N., Jones, D. L., Tan, Q., Meridew, J., Diaz Espinosa, A. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau6296 · Cited by 218 · cited 2×
“Recently, YAP/TAZ deletion in Gli(1) fibroblasts was shown to reverse fibrosis development in the mouse kidney (63), and fibroblast-selective YAP/TAZ inhibition through DRD1 agonism was able to reverse lung fibrosis and reduce liver fibrosis in mouse models (17).”
BackgroundSelf-citationDefining the Activated Fibroblast Population in Lung Fibrosis Using Single-Cell Sequencing
Peyser, R., MacDonnell, S., Gao, Y., Cheng, L., Kim, Y., Kaplan, T., Ruan, Q., Wei, Y., Ni, M., Adler, C., et al. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0313oc · Cited by 210 · cited 1×
“Because of the lack of broad fibroblast markers (45), we focused on lung cells expressing high levels of collagen, as this population is highly enriched in fibroblasts (46).”
BackgroundFoster, C. T., Gualdrini, F., & Treisman, R. (2017) · Genes & Development · doi:10.1101/gad.304501.117 · Cited by 202
Drug targeting to myofibroblasts: Implications for fibrosis and cancer
Yazdani, S., Bansal, R., & Prakash, J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.010 · Cited by 189 · cited 1×
“promising therapeutic strategy for fibrotic diseases (9).”
DNA binding partners of YAP/TAZ
Kim, M.-K., Jang, J.-W., & Bae, S.-C. (2018) · BMB Reports · doi:10.5483/bmbrep.2018.51.3.015 · Cited by 181 · cited 1×
“However, YAP also binds other transcription factors, including p73, RUNXs, SMADs, EGR1, and TBX5, which would not be detected in that assay (51).”
BackgroundOku, Y., Nishiya, N., Shito, T., Yamamoto, R., Yamamoto, Y., Oyama, C., & Uehara, Y. (2015) · FEBS Open Bio · doi:10.1016/j.fob.2015.06.007 · Cited by 179 · cited 1×
“Two smaller scalescreens have employed a similar strategy to ours and identified statins as YAP/TAZ inhibitors in breast cancer epithelial cells (19, 54).”
Yap/Taz deletion in Gli(+) cell-derived myofibroblasts attenuates fibrosis
Liang, M., Yu, M., Xia, R., Song, K., Wang, J., Luo, J., Chen, G., & Cheng, J. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015121354 · Cited by 169 · cited 1×
“Recently, YAP/TAZ deletion in Gli(1) fibroblasts was shown to reverse fibrosis development in the mouse kidney (63), and fibroblast-selective YAP/TAZ inhibition through DRD1 agonism was able to reverse lung fibrosis and reduce liver fibrosis in mouse models (17).”
BackgroundRole of RhoA Inactivation in Reduced Cell Proliferation of Human Airway Smooth Muscle by Simvastatin
Takeda, N., Kondo, M., Ito, S., Ito, Y., Shimokata, K., & Kume, H. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0034oc · Cited by 146 · cited 12×
“We thus investigated whether YAP inactivation by statins could be reversed by addition of GGPP to the culture media.”
BackgroundInfluentialStatins and Pulmonary Fibrosis: The Potential Role of NLRP3 Inflammasome Activation
Xu, J.-F., Washko, G. R., Nakahira, K., Hatabu, H., Patel, A. S., Fernandez, I. E., Nishino, M., Okajima, Y., Yamashiro, T., Ross, J. C., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201108-1574oc · Cited by 141
Maguire, O., Collins, C., O'Loughlin, K., Miecznikowski, J., & Minderman, H. (2011) · Cytometry Part A · doi:10.1002/cyto.a.21068 · Cited by 124
Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C
Simon, T. G., King, L. Y., Zheng, H., & Chung, R. T. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.013 · Cited by 114
Watts, K. L., Sampson, E. M., Schultz, G. S., & Spiteri, M. A. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0127oc · Cited by 109
Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis
Nadrous, H. F., Pellikka, P. A., Krowka, M. J., Swanson, K. L., Chaowalit, N., Decker, P. A., & Ryu, J. H. (2004) · CHEST Journal · doi:10.1378/chest.126.2.438 · Cited by 105
Watts, K., & Spiteri, M. A. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00447.2003 · Cited by 104
Therapeutic Targeting of TAZ and YAP by Dimethyl Fumarate in Systemic Sclerosis Fibrosis
Toyama, T., Looney, A. P., Baker, B. M., Stawski, L., Haines, P., Simms, R., Szymaniak, A. D., Varelas, X., & Trojanowska, M. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.08.024 · Cited by 101
Statins and Interstitial Lung Disease
Fernández, A. B., Karas, R. H., Alsheikh-Ali, A. A. A., & Thompson, P. D. (2008) · CHEST Journal · doi:10.1378/chest.08-0943 · Cited by 98
Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
Kreuter, M., Bonella, F., Maher, T. M., Costabel, U., Spagnolo, P., Weycker, D., Kirchgaessler, K.-U., & Kolb, M. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208819 · Cited by 85
Genetic tools for identifying and manipulating fibroblasts in the mouse
Swonger, J. M., Liu, J. S., Ivey, M. J., & Tallquist, M. D. (2016) · Differentiation · doi:10.1016/j.diff.2016.05.009 · Cited by 84
Yap/Taz mediates mTORC2-stimulated fibroblast activation and kidney fibrosis
Gui, Y., Li, J., Lu, Q., Ye, F., Wang, M., He, W., Yang, J., & Dai, C. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004073 · Cited by 79
Monceau, V., Pasinetti, N., Schupp, C., Pouzoulet, F., Opolon, P., & Vozenin, M. (2010) · Current Drug Targets · doi:10.2174/1389450111009011395 · Cited by 74
Zhu, B., Ma, A., Yang, L., & Dang, X. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141224476 · Cited by 69
Tanaka, K., Osada, H., Murakami‐Tonami, Y., Horio, Y., Hida, T., & Sekido, Y. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.020 · Cited by 69 · cited 1×
“Statins have been shown to regulate YAP in epithelial breast cancer and mesothelioma cell lines by preventing GGPP-mediated RhoA activation and actin fiber formation (20, 21).”
BackgroundSimvastatin inhibits TGFβ1-induced fibronectin in human airway fibroblasts
Schaafsma, D., McNeill, K. D., Mutawe, M. M., Ghavami, S., Unruh, H. W., Jacques, É., Laviolette, M., Chakir, J., & Halayko, A. J. (2011) · Respiratory Research · doi:10.1186/1465-9921-12-113 · Cited by 64
Melatonin Protects against Lung Fibrosis by Regulating the Hippo/YAP Pathway
Zhao, X., Sun, J., Su, W., Shan, H., Zhang, B., Wang, Y., Shabanova, A., Shan, H., & Liang, H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041118 · Cited by 64
Nadrous, H. F., Ryu, J. H., Douglas, W. W., Decker, P. A., & Olson, E. J. (2004) · CHEST Journal · doi:10.1016/s0012-3692(15)31155-7 · Cited by 61
Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis
Kreuter, M., Costabel, U., Richeldi, L., Cottin, V., Wijsenbeek, M. S., Bonella, F., Bendstrup, E. M., Maher, T. M., Wachtlin, D., Stowasser, S., et al. (2018) · Respiration · doi:10.1159/000486286 · Cited by 61
Krempen, K., Grotkopp, D., Hall, K. L., Bache, A., Gillan, A., Rippe, R. A., Brenner, D. A., & Breindl, M. (1999) · Europe PMC (PubMed Central) · Cited by 59
The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ
Zmajkovicova, K., Menyhart, K., Bauer, Y., Studer, R. O., Renault, B., Schnoebelen, M., Bolinger, M., Nayler, O., & Gatfield, J. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0142oc · Cited by 59
Statins and the risk of interstitial lung disease: a cohort study
Saad, N., Camus, P., Suissa, S., & Ernst, P. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-201823 · Cited by 56
Hao, F., Xu, Q., Wang, J., Yu, S., Chang, H.-H., Sinnett-Smith, J., Eibl, G., & Rozengurt, E. (2019) · PLOS ONE · doi:10.1371/journal.pone.0216603 · Cited by 55 · cited 2×
“Cerivastatin and simvastatin have been shown to induce S127-YAP phosphorylation in MDA-MB-231 breast cancer cells (19, 20), but not in human pancreatic cancer cells (55).”
BackgroundWuyts, W. A., Dahlqvist, C., Slabbynck, H., Schlesser, M., Gusbin, N., Compere, C., Maddens, S., Kirchgaessler, K.-U., Bartley, K., & Bondue, B. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000331 · Cited by 54 · cited 1×
“Indeed, a considerable proportion of patients with IPF are also prescribed statins for comorbidities (70).”
BackgroundPleiotropic effects of statins in the diseases of the liver
Janicko, M., Drazilova, S., Pella, D., Fedacko, J., & Jarcuska, P. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i27.6201 · Cited by 53 · cited 1×
“There is also evidence that statins reduce liver fibrosis progression (75, 76).”
BackgroundEffect of pravastatin on bleomycin‐induced acute lung injury and pulmonary fibrosis
Kim, J. W., Rhee, C. K., Kim, T. J., Kim, Y. H., Lee, S. H., Yoon, H. K., Kim, S. C., Lee, S. Y., Kwon, S. S., Kim, K. H., et al. (2010) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2010.05431.x · Cited by 52
Jin, H., Lian, N., Zhang, F., Bian, M., Chen, X., Zhang, C., Jia, Y., Lu, C., Hao, M., Yao, S., et al. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.10.002 · Cited by 52
Simvastatin attenuates bleomycin-induced pulmonary fibrosis in mice
Ou, X., Feng, Y., Wen, F., Huang, X., Xiao, J., Wang, K., & Wang, T. (2008) · Chinese Medical Journal · doi:10.1097/00029330-200809020-00013 · Cited by 50
Michalik, M., Soczek, E., Kosińska, M., Rak, M., Wójcik‐Pszczoła, K., Lasota, S., Pierzchalska, M., Czyż, J., & Madeja, Z. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.02.023 · Cited by 42
Statin Use Is Associated with Reduced Mortality in Patients with Interstitial Lung Disease
Vedel‐Krogh, S., Nielsen, S. F., & Nordestgaard, B. G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140571 · Cited by 38
Wu, P., Liu, Z., Zhao, T., Xia, F., Gong, L., Zheng, Z., Chen, Z., Yang, T., & Duan, Q. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.158 · Cited by 38
Inhibitory effects of pitavastatin on fibrogenic mediator production by human lung fibroblasts
Oka, H., Ishii, H., Iwata, A., Kushima, H., Toba, S., Hashinaga, K., Umeki, K., Tokimatsu, I., Hiramatsu, K., & Kadota, J. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.10.026 · Cited by 15
Hritzo, M. K., Courneya, J.-P., & Golding, A. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.01.001 · Cited by 12 · cited 1×
“To address this issue, we used imaging flow cytometry (IFC) to quantify intracellular nucleocytoplasmic translocation events in immunophenotypically defined cell populations (42, 43).”
MethodHamblin, M. J., Eberlein, M. H., Black, K. E., Hallowell, R. W., Collins, S. L., Chan‐Li, Y., & Horton, M. R. (2014) · International Journal of Biomedical Science · doi:10.59566/ijbs.2014.10146 · Cited by 11
Self-citation
Research works printed but not linked: 1
- Santos, 2019, A high-throughput small molecule screen for YAP inhibitors identifies statins as inhibitors of fibroblast activation and pulmonary fibrosis [abstract], A5878
Cited by
The extracellular matrix and mechanotransduction in pulmonary fibrosis
Deng, Z., Fear, M. W., Suk Choi, Y., Wood, F. M., Allahham, A., Mutsaers, S. E., & Prêle, C. M. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105802 · Cited by 120
New Insights into Hippo/YAP Signaling in Fibrotic Diseases
Mia, M. M., & Singh, M. K. (2022) · Cells · doi:10.3390/cells11132065 · Cited by 116
“This study found that simvastatin modulates YAP localization in mouse lung fibroblasts in vivo and reduces established fibrosis in bleomycin-challenged mouse IPF (Table 1) [67].”
BackgroundInfluentialFibrosis: cross-organ biology and pathways to development of innovative drugs
Rieder, F., Nagy, L. E., Maher, T. M., Distler, J. H. W., Kramann, R., Hinz, B., & Prunotto, M. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01158-9 · Cited by 151
“Several statins recently emerged from high-throughput screens with small-molecule libraries as possible regulators of YAP signalling and drugs that target the mevalonate pathway in human lung fibroblasts 126 .”
YAP/TAZ: Molecular pathway and disease therapy
Wei, Y., Hui, V. L. Z., Chen, Y., Han, R., Han, X., & Guo, Y. (2023) · MedComm · doi:10.1002/mco2.340 · Cited by 122
Hippo signaling pathway and respiratory diseases
Tang, W., Li, M., Yangzhong, X., Zhang, X., Zu, A., Hou, Y., Li, L., & Sun, S. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01020-6 · Cited by 90
“Lung fibroblasts are the main effector cells of IPF, and the YAP mediates the proliferation, migration, and collagen deposition of lung fibroblasts induced by mechanical signals [100, 101].”
Background
Metadata
- Authors
- Santos, D. M., Pantano, L., Pronzati, G., Grasberger, P., Probst, C. K., Black, K. E., Spinney, J. J., Hariri, L. P., Nichols, R., Lin, Y., Bieler, M., Seither, P., Nicklin, P., Wyatt, D., Tager, A. M., & Medoff, B. D.
- Affiliations
- Division of Pulmonary and Critical Care Medicine, and
- Harvard University (US)
- Computational Chemistry
- Business Development and Licensing
- Research Beyond Borders, and
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Medoff, Benjamin D.
- ORCID
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-04-01
- Volume
- 62
- Issue
- 4
- Pages
- 479-492
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- PMC
- PMC7110981
- OpenAlex
- W3003235367
- Cited by
- 72
- References
- 76
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 15 · 2023: 15 · 2022: 12 · 2021: 7 · 2020: 3
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Respiratory Cell and Molecular Biology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL133153, K08HL133603)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- YAP, YAP inhibitor, statins, simvastatin, idiopathic pulmonary fibrosis, lung fibroblasts, fibroblast activation, mevalonate pathway, YAP phosphorylation, antifibrotic agents, bleomycin-induced fibrosis
- MeSH terms
- YAP-Signaling Proteins, Acyl Coenzyme A, Animals, Bleomycin, Cell Nucleus, Cytoplasm, Fibroblasts, Humans, Mevalonic Acid, Phosphoproteins, Pulmonary Fibrosis, Signal Transduction, Biomarkers, Cell Cycle Proteins, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin, Adaptor Proteins, Signal Transducing, Mice, Small Molecule Libraries
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.